Similar Items: Pharmacogenomics of sickle cell disease therapeutics: pain and drug metabolism associated gene variants and hydroxyurea-induced post-transcriptional expression of miRNAs
- MiRNAs levels in a Streptozocin model of Alzheimer’s disease
- Polymeric delivery of miRNA therapeutics
- Regulatory networks in non-small cell lung cancer: Connecting differentially expressed genes, miRNAs, and incRNAs
- MRI Features and Significance of Serum miRNAs and Inflammatory Cytokines in Patients with Temporal Lobe Epilepsy
- Candidate Biomarkers for Crohn’s Disease: Hub Genes and Regulatory miRNAs Identified by Bioinformatics Analysis
- Expression Variation of Candidate miRNAs in Prostate Cancer: A Gel Electrophoresis Based Approach
Author: Wonkam, Ambroise
- Association of variants in APOL1, MYH9 and HMOX1 WITH micro-Albuminuria among Sickle Cell disease patients from Cameroon
- Sickle cell anaemia in Cameroon : co-inheritance of α-thalassemia, HBB gene haplotypes, clinical & haematological characterisations
- Study of genetic modifiers of fetal hemoglobin and mechanisms of hydroxyurea-induced γ-globin expression in sickle cell disease
- Return of a Fragile X Syndrome Genetic Result: Exploring the feedback of Individual genetic findings and their relation to traditional knowledge in a village in Cameroon
- The genetics of non-syndromic hearing impairment in South Africa
- Knowledge and experiences of parents with children affected by Sickle Cell Disease in Cape Town